Impact of comorbidities on COVID-19 outcome

Abstract

Background and aims: The coronavirus disease 19 (COVID-19) pandemic has spread rapidly around the globe with considerable morbidity and mortality. Coexistence of comorbidities with COVID-19 have consistently been reported as risk factors for unfavorable prognosis. We aim at this study to evaluate the impact of comorbidities in COVID-19 patients on the outcome and determine predictors of prolonged hospital stay, requisite for ICU admission or decease. Methods: Four hundreds and thirty nine adult patients who are admitted through (June and July 2020) in Assiut and Aswan University Hospitals were included in the study. All participants were diagnosed with COVID-19 according to Egyptian Ministry of Health guidance as definite case or Probable case. Detection of SARS-CoV-2 RNA was done by (TaqMan 2019-nCoV Control Kit v1 (Cat. No. A47532) supplied by QIAGEN, Germany on the Applied Biosystem 7500 Fast RT PCR System, USA. Results: Patients with comorbidities represented 61.7% of all cases. Constitutional symptoms especially myalgia and LRT symptoms such as dyspnea were significantly higher in patients with comorbidities (P < 0.05). Patients with comorbidities had significantly worse laboratory parameters. ICU admission was higher in patients with comorbidities (35.8%). Among different comorbidities 45.4% of CVD cases were admitted in ICU followed by DM cases (40.8%). Also, patients with comorbidities needed invasive mechanical ventilation more than those without comorbidity (31 vs. 10.7%, P<0.001). Significant lower frequency of recovery was found in COVID-19 patients with comorbidities (59% vs. 81%, P<0.001) and death rate was significantly higher in cases with comorbidities (P< 0.001). The survival rates in cases with pre-existing CVD and neurological diseases were lower than those without disease (P<0.002 and 0.001 respectively). Conclusion: Association of cardiovascular comorbid conditions including hypertension or neurological diseases together with COVID-19 infections carries higher risks of mortality. However, other comorbidities such as diabetes mellitus, chronic pulmonary or kidney diseases may also contribute to increased COVID-19 severity.

The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study

“…This study utilized results obtained from Open Epi, version 3, open-source calculator—SSCC, for the data extracted from another Egyptian study [ 10 ]. A minimal sample size of 180 was indicated.…”

Hubungan Komorbiditas Terhadap Derajat Keparahan Admisi Dan Outcome Pasien Covid-19

“…Hasil penelitian ini sesuai dengan penelitian Khedr et al (2020) menunjukan bahwa pasien dengan komorbid memiliki parameter laboratorium yang secara signifikan lebih buruk. Pasien yang memiliki komorbid (35,8%) membutuhkan perawatan intensif dibandingkan dengan pasien yang tanpa komorbid (16,4%), dan tingkat kematian juga secara signifikan lebih tinggi dalam kasus pasien dengan komorbid (p<0,001) (Khedr et al, 2020).…”

“…Secara umum, salah satu pertimbangan klinis yang paling mengkhawatirkan adalah adanya komorbid pada pasien. Keadaan komorbid dikaitkan dengan hasil kesehatan yang lebih buruk, manajemen klinis yang lebih kompleks, dan peningkatan biaya perawatan kesehatan (Khedr et al, 2020). Berdasarkan penelitian Wei-jie et al (2020), pasien yang terkonfirmasi COVID-19 dengan komorbid menghasilkan outcome klinis yang lebih buruk daripada mereka yang tidak.…”

U.S. COVID-19 Policy: Politics Trump Science

“…148 The exacerbation of comorbidities is also an important part of understanding COVID-19's potential for lifealtering or life-ending impact. 149,150 Long COVID also poses threats to health and longevity. Long COVID is characterized by a range of symptoms, which typically include shortness of breath, fatigue, fever, headaches, "brain fog" and other neurological problems.…”